Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PTPN1 | P18031 | 5/20 | 0.48 |
| ▸ | SCN9A | Q15858 | 8/20 | 0.37 |
| ▸ | F10 | P00742 | 5/20 | 0.37 |
| ▸ | PRSS1 | P07477 | 5/20 | 0.35 |
| ▸ | F2 | P00734 | 3/20 | 0.35 |
| ▸ | PRSS2 | P07478 | 3/20 | 0.35 |
| ▸ | PRSS3 | P35030 | 3/20 | 0.35 |
| ▸ | PLG | P00747 | 1/20 | 0.35 |
| ▸ | PLAT | P00750 | 1/20 | 0.35 |
| ▸ | F7 | P08709 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL7595028 | 0.87 | ALOX5AP (0.40) | PTPN1 | |
| SCHEMBL7198006 | 0.84 | PTPN1 (0.42) | PTPN1 | |
| SCHEMBL7663140 | 0.83 | PTPN1 (0.44) | PTPN1 | |
| SCHEMBL7592239 | 0.82 | PTPN1 (0.50) | PTPN1 | |
| SCHEMBL7188776 | 0.81 | PTPN1 (0.49) | PTPN1 | |
| SCHEMBL7595806 | 0.78 | PTPN1 (0.39) | PTPN1 | |
| SCHEMBL7594097 | 0.78 | PTPN1 (0.76) | PTPN1SCN9AF10PRSS1F2 | |
| SCHEMBL7193468 | 0.77 | PTPN1 (0.45) | PTPN1 | |
| SCHEMBL7595311 | 0.77 | PTPN1 (0.39) | PTPN1 | |
| SCHEMBL7189794 | 0.74 | PTPN1 (0.40) | PTPN1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-6498151-B2 | PROTEIN TYROSINE PHOSPHATASES INHIBITORS, ESPECIALLY AS ANTIDIABETIC AGENTS | MERCK FROSST CANADA & CO. (CA) | 2002-12-24 | — | — | US | claimed |
| US-6498151-B2 | PROTEIN TYROSINE PHOSPHATASES INHIBITORS, ESPECIALLY AS ANTIDIABETIC AGENTS | MERCK FROSST CANADA & CO. (CA) | 2002-12-24 | — | — | US | disclosed |
| US-20020091104-A1 | Aryldifluoromethylphosphonic acids with sulfur-containing substituents as PTP-1B inhibitors | MERCK FROSST CANADA LTD. (CA) | 2002-07-11 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20020091104-A1 | Aryldifluoromethylphosphonic acids with sulfur-containing substituents as PTP-1B inhibitors | PTPRF, PTPRS, PTPRO | PTPN1 13/4885SCN9A 863/4885F10 4412/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.